Clinical outcome and atherothrombogenic risk profile after prolonged wash-out following long-term treatment with high doses of n-3 PUFAs in patients with an acute myocardial infarction.
BACKGROUND
Sustained effects following withdrawal of n-3 PUFAs are unknown.


METHODS
Clinical outcome [cardiac death, resuscitation, recurrent myocardial infarction (MI) or unstable angina pectoris] was assessed after prolonged wash-out following randomised treatment with high-dosed n-3 PUFAs or corn oil for 12-24 months in 300 acute MI patients. Atherothrombogenic risk markers, serum glucose and markers of lipid peroxidation and inflammation were evaluated in 89 out of the 100 last included patients.


RESULTS
After a total median observation period of 45 (range 0-53) months no intergroup difference in prognosis was observed for any of the cardiac events. Favourable effects on serum triglycerides and HDL-cholesterol by n-3 PUFAs were lost after washout, but triglycerides decreased in the corn oil as compared to the n-3 group, P < 0.001. The decline in total cholesterol after withdrawal was similar in both groups. No intergroup difference in the change in thiobarbituric acid-malondialdehyde, a marker of lipid peroxidation, ultrasensitive C-reactive protein, homocysteine, glucose or blood platelets was noted at sustained follow-up.


CONCLUSIONS
Clinical outcome was similar in both patient groups, and the atherothrombogenic risk improvement by n-3 PUFAs was lost after prolonged wash-out. Withdrawal did not affect homocysteine, glucose or markers of lipid peroxidation or inflammation.
Department of Medicine, Rogaland Central Hospital, P.O. Box 8100, Stavanger 4068, and University of Bergen, Norway. heidi@madlalia.no
Heidi
H
Grundt
Dennis W T
DW
Nilsen
Øyvind
Ø
Hetland
Mohammad A
MA
Mansoor
D000208:Acute Disease; D000368:Aged; D001786:Blood Glucose / Q000032:analysis; D002097:C-Reactive Protein / Q000032:analysis; D008076:Cholesterol, HDL / Q000097:blood*; D003314:Corn Oil; D004305:Dose-Response Relationship, Drug; D015525:Fatty Acids, Omega-3 / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006710:Homocysteine / Q000097:blood; D006801:Humans; D015227:Lipid Peroxidation; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood / Q000178:diet therapy*; D011379:Prognosis; D012189:Retrospective Studies; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome; D014280:Triglycerides / Q000097:blood*
D001786:Blood Glucose; D008076:Cholesterol, HDL; D015525:Fatty Acids, Omega-3; D014280:Triglycerides; D006710:Homocysteine; D003314:Corn Oil; D002097:C-Reactive Protein